Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma (NCT07450040)

Study summary

In the past 10 years, there have been many effective explorations on the treatment of NK/TCL at home and abroad, which has innovated the treatment mode. Since ENKTCL-NT cells are sensitive to radiotherapy, radiotherapy is considered to be the most reliable treatment for ENKTCL-NT. Although patients with radiotherapy alone have excellent short-term efficacy and can achieve CR in 70-97% of patients, the 5-year PFS is only 30.5-61%, with a higher recurrence rate 5,6. The combination of chemotherapy and radiotherapy significantly improved the survival of patients compared with historical controls. Recent studies have shown that the advantage of radiotherapy combined with chemotherapy is that it can significantly reduce the later recurrence of patients with radiotherapy alone. However, the traditional synchronous chemotherapy and radiotherapy have many and serious adverse reactions and poor tolerance in patients, so it cannot be widely applied.

Conditions studied

In context

Lead sponsor

Eye & ENT Hospital of Fudan University is the lead sponsor of 121 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 70 Years
Sexes eligible: All
Sampling method: Non-probability sample

Study population

This study was conducted in patients with primary stage I-II NK/ T-cell lymphoma (subjects must have a measurable tumor lesion at baseline).

Inclusion criteria

Clinical diagnosis of NK/T cell lymphoma .
Stage I/II patients .
Age 18-70.
ECOG score 0-2 points.
Sign informed consent.
Voluntary compliance with research protocols, follow-up plans, laboratory and auxiliary examinations.

Exclusion criteria

Exclusion Criteria:

Patients with HCV or HIV infection and HBV infection receiving antiviral therapy at the same time are not excluded.
Complicated with severe infection requires ICU treatment.
There are serious complications such as hemophagic syndrome, DIC, etc.
Functional impairment of major organs.
A history of autoimmune disease.
Pregnant or lactating women.
Patients with a history of psychotropic drug abuse who cannot abstain or have mental disorders.
Patients who are known to be allergic to drugs used in chemotherapy regimens.
Patients with other tumors requiring surgery or chemotherapy within 6 months.
Patients who have participated in other clinical trials within 4 weeks prior to the trial;
Patients who are taking other investigational drugs.
Patients with severe allergic history or allergic constitution.
The target lesion has received radiation therapy or surgery (except biopsy);
Previously used chemotherapy, immunotherapy or biological targeted therapy for the primary tumor.

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 60 participants (estimated)
Target follow-up: 3 Years
Patient registry: Yes

What researchers measure

Primary outcomes

ORR
Objective Response Rate; The proportion of patients who achieved pre-specified tumor volume reduction and maintained the minimum time frame required by accepted response evaluation criteria, such as Solid Tumor RECIST Version 1.1.
Time frame: At 14 weeks after treatment initiation

Secondary outcomes

PFS
progression free survival; It refers to the time between the start of treatment and the onset of disease progression or death from any cause
Time frame: up to 5 year

Study locations

1 site

EENT hospital of Fudan University
Shanghai, China 200000, China

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07450040
Lead sponsor: Eye & ENT Hospital of Fudan University
Responsible party: Sponsor
First posted: Mar 4, 2026
Start date: Sep 12, 2024
Primary completion: Jul 31, 2027 (estimated)
Completion: Dec 31, 2027 (estimated)
Last update: Mar 4, 2026

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma